Allena Pharmaceuticals, Inc.
ALNAQ
Other OTC0.00
USD
+0.00
- -
CIK
0001624658
Return %
Stock
S&P500
1Y
-99.99
19.01
3Y
-100.00
65.48
5Y
-100.00
72.20
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Full Time Employees
- 12
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- One Newton Executive Park Newton MA United States of America 02462
- IPO Date
- Nov 2, 2017
- CIK
- 0001624658
- Website
- allenapharma.com
- Similar Companies
- Business
- Allena Pharmaceuticals, Inc. (ALNAQ) is a biopharmaceutical company that discovers, develops, and commercializes oral enzyme therapeutics to treat patients with rare and severe metabolic and kidney disorders, including hyperuricemia, gout, enteric hyperoxaluria, and related conditions in patients with advanced chronic kidney disease; its lead product candidates include ALLN-346, a novel urate-degrading enzyme, and reloxaliase (ALLN-177), an oral enzyme for reducing urinary oxalate levels in hyperoxaluria. Founded in 2011 and headquartered in Newton, Massachusetts, the company operates primarily in the United States through wholly owned subsidiaries such as Allena Pharmaceuticals Security Corporation and Allena Pharmaceuticals Ireland Limited, targeting unmet needs in nephrologic and urologic conditions with non-systemic, orally administered biologics that act in the gastrointestinal tract. In September 2022, Allena filed a voluntary Chapter 11 petition for reorganization in the U.S. Bankruptcy Court for the District of Delaware, followed by court approval of a Chapter 11 liquidation plan on May 18, 2023, resulting in the cessation of operations, cancellation of outstanding shares without distribution to shareholders, termination of nearly all employees including key executives, and discontinuation of clinical programs such as the URIROX-2 study for reloxaliase; as of 2025, the company remains in asset liquidation under ongoing bankruptcy proceedings with no active development or commercialization activities.